Somerset CM replaces Jupiter AM as manager of Omnis EM opps fund
Events
If you already have an account please use the link below to sign in.
If you have any problems with your access or would like to request an individual access account please contact our customer service team.
White and Robertson to lead management
Somerset Capital Management s Christopher White
Omnis Investments has appointed Somerset Capital Management to run its £322m AUM Global Emerging Markets Equity Opportunities fund, replacing Jupiter Asset Management in a shift designed to provide the best outcomes for clients and advisers .
The appointment, which takes effect from today (8 April), follows a whole of market selection process led by Omnis team and supported by independent investment consultants Fundhouse.
Icosavax lands $100M to take its virus-like particle vaccines into clinical trials
Icosavax lands $100M to take its virus-like particle vaccines into clinical trials
RA Capital led the $100 million Series B round of funding for Icosavax, a startup developing vaccines based on virus-like particles. The biotech is preparing for clinical tests of vaccines for respiratory syncytial virus, human metapneumovirus, and SARS-CoV-2.
Shares0
Icosavax has drawn up clinical trial plans for its new type of vaccine in a strategy to commence tests of multiple programs, including a Covid-19 candidate. But really, the startup is following a path blazed by Mother Nature.
Icosavax Closes $100 Million Series B Financing to Advance Bivalent RSV/hMPV Vaccine Candidate Into Clinical Trials streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
April 1, 2021
By Bio-IT World Staff
April 1, 2021 | New investment funds for late-stage companies and public health. Next-gen genomic medicines and single-cell multiomics get cash, and PatientsLikeMe raises a new round of funding to expand.
$969M Investment Fund for Early to Late-Stage Companies
Foresite Capital, a multi-stage healthcare and life sciences investment firm, has announced its fifth and largest fundraise with $969 million in capital commitments, significantly oversubscribed above its original target. The offering comprises Foresite Capital Fund V, L.P. and Foresite Capital Opportunity Fund V, L.P. With these new funds, Foresite Capital is investing in emerging healthcare and life sciences companies at all stages that are solving some of the biggest inefficiencies and pain points of the $10 trillion global healthcare market. Foresite Capital now has ~$4 billion in assets under management. Press release.
U S Stock ETFs Climb Ahead of Biden s Infrastructure Announcement etftrends.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etftrends.com Daily Mail and Mail on Sunday newspapers.